ClinicalTrials.gg
Not yet recruitingNCT07652515Updated Jun 17, 2026

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer

A Phase 4 interventional study of Dostarlimab and Carboplatin in Neoplasms, Endometrial, sponsored by GlaxoSmithKline. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing dostarlimab in Endometrial Neoplasms — 12 open to participants now, 17 under way, 3 of them phase 3. dostarlimab · Endometrial Neoplasms.

Planned enrollment
6th of 18
100 · median 46
Started
2026
with 2 others
Phase 4
2 of 18
2 open now
Primary completion
2030-08
later than 14 of 16 live
Registered
16th of 18
by date
Lead sponsor
5 of 18
GlaxoSmithKline

Among the 18 studies testing dostarlimab in Endometrial Neoplasms, this one is the 6th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 4, reaches primary completion later than 14 of the 16 other live ones, and was the 16th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

12 of the 18 studies testing dostarlimab in Endometrial Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About dostarlimab

dostarlimab: first FDA approval 2021 (JEMPERLI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing dostarlimab in Endometrial Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).

03

Conditions studied

  • Neoplasms, Endometrial

Keywords

  • Carboplatin
  • Dostarlimab
  • Endometrial cancer
  • First line treatment
  • Paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with greater than or equals to (>=) 18 years of age, at the time of signing the .
  • Participant has or cytologically proven EC with recurrent or advanced disease.
  • Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination based on investigator's assessment.
  • Eligible for dostarlimab treatment according to the approved prescribing information and the investigator's clinical judgement.
  • Woman of (WOCBP) agrees to use from screening through at least 180 days after the last dose.
  • Negative urine pregnancy test at most 24 hours prior to the first dose of study intervention.
  • Capable of giving signed informed consent.
  • Participant has an (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Participant has had greater than (>) 1 recurrence of endometrial cancer.
  • Participant has a concomitant , or participant has a prior non endometrial invasive malignancy who has been disease-free for less than (\<) 3 years or who received any active treatment in the last 3 years for that malignancy.
  • Participant has known uncontrolled central nervous system , carcinomatosis meningitis, or both.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy.
  • Participant has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.
  • Participant has not recovered (i.e., to Grade less than or equal to [\<=] 1 or to Baseline) from cytotoxic therapy induced AEs or has received transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], Granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 21 days prior to the first dose of study drug.
  • Either the history of to of the study intervention or to drugs with a similar chemical structure or class of the study intervention.
  • Participant has known active (e.g., hepatitis B surface antigen reactive) or (e.g., hepatitis C virus ribonucleic acid [qualitative] is detected).
  • Participant has received /adjuvant systemic anticancer therapy for primary Stage III or IV disease and:

    • has not had a recurrence or Progressive disease (PD) prior to first dose on the study, or
    • has had a recurrence or PD within 6 months of completing systemic anticancer therapy treatment prior to first dose on the study.
  • Participant has received prior therapy with an anti- Programmed death protein 1 (), anti- Programmed death ligand 1 (anti-PD-L1), or Programmed death ligand 2 (anti PD L2) agent.
  • Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days or \<5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.
  • Systemic for any purpose other than to manage symptoms of suspected irAEs. If medically deemed necessary (e.g., acute asthma or exacerbation, prophylaxis for intravenous (IV) contrast if indicated), Investigators are allowed to use their judgment to treat participants with systemic steroids. In such cases, systemic steroids should be stopped at least 24 hours prior to the next dose of study treatment.
  • Participant has received, or is scheduled to receive, a within 30 days before first dose of study intervention, during study treatment, and for up to 180 days after receiving the last dose of study intervention.
  • Participant has a diagnosis of immunodeficiency and is receiving systemic steroid therapy (>10 milligrams [mg] daily prednisone or equivalent) within 7 days prior to the first dose of the study treatment or is receiving any other form of medication.
  • Participant is currently receiving study intervention, or is enrolled or has participated in any other clinical study involving an intervention and received investigational treatment or used an investigational device within 4 weeks of the first dose of dostarlimab.
  • Participant is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study intervention.
  • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Participants receiving Dostarlimab with Carboplatin + Paclitaxel followed by Dostarlimab Monotherapy

    Participants will receive dose level 1 of dostarlimab in combination with carboplatin and paclitaxel followed by dose level 2 of dostarlimab monotherapy. Dose level 1 is the lowest dose level.

    Drug: Dostarlimab · Drug: Carboplatin · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Grade 3 or greater treatment-emergent adverse events (TEAEs) up to Week 49

    Time frame: Up to Week 49

Secondary outcomes

  1. Number of participants with Grade 3 or greater TEAEs up to Week 170

    Time frame: Up to Week 170

  2. Number of participants with TEAEs up to Week 49

    Time frame: Up to Week 49

  3. Number of participants with TEAEs up to Week 170

    Time frame: Up to Week 170

  4. Number of participants with Immune-related adverse events (irAEs) up to Week 49

    Time frame: Up to Week 49

  5. Number of participants with Immune-related adverse events (irAEs) up to Week 170

    Time frame: Up to Week 170

  6. Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 49

    Time frame: Up to Week 49

  7. Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 170

    Time frame: Up to Week 170

  8. Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 49

    Time frame: Up to Week 49

  9. Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 170

    Time frame: Up to Week 170

  10. Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  11. Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  12. Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  13. Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  14. Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 49

    Time frame: Baseline (Day 1) and up to 49

  15. Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  16. Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  17. Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  18. Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  19. Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) to up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  20. Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  21. Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  22. Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  23. Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  24. Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  25. Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  26. Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  27. Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  28. Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  29. Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  30. Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  31. Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  32. Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  33. Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  34. Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  35. Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  36. Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  37. Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

  38. Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 49

    Time frame: Baseline (Day 1) and up to Week 49

  39. Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 170

    Time frame: Baseline (Day 1) and up to Week 170

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2030, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 17, 2026
StartEst.
Aug 17, 2026
Primary completionEst.
Aug 30, 2030
CompletionEst.
Aug 30, 2030
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07652515
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Aug 17, 2026 (estimated)
Primary completion
Aug 30, 2030 (estimated)
Completion
Aug 30, 2030 (estimated)
Last update
Jun 17, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion